Table 1. Patient response to ‘booster' K562/GM-CSF vaccination series in trial J0625.

ID	Age	Sex	Weeks between primary and boost vaccination	Time on TKI prior to boost vaccination series (wks)	BCR–ABL PCR pre-primary vaccination (J0345)	BCR–ABL PCR postprimary vaccination (J0345)	BCR–ABL PCR pre-boostvaccination (J0625)	BCR–ABL PCR post-boostvaccination (J0625)	Time from boost vaccination to lowest PCR (weeks)
12	78	M	81	275	14	3.6	2	0.2	12
10	60	F	84	337	109	153	41	2.4	24
17	48	M	82	322	9.4	1.3	0.5	0.2	48
14	61	M	93	329	16	42	28	166	12
2	60	F	141	351	69	26	<0.05	0.3	36
1	63	M	122	266	28	<0.05	<0.05	<0.05	24
19	37	M	77	167	7.9	4.9	12	1	24
3	38	M	108	187	1.5	0.7	0.6	0.1	12
5	32	F	199	294	0.1	0	<0.05	0	48
7	68	F	107	305	0.3	0.2	0.07	0.1	36
9	49	M	131	233	69	6.4	0.08	0	48

Patient demographic and clinical response data for those patients enrolled on both initial (J0345) and boost (J0625) clinical protocols. All patients remained on tyrosine kinase inhibitor (TKI) therapy during and between both protocols. PCR was performed every 6 weeks during each study using patient peripheral blood as previously described³⁸ and is reported in terms of number of BCR–ABL fusion transcripts detected per 1000 ABL reference transcripts. Orange (<0.05) represents non-quantifiable levels of minimal residual disease, red (0) denotes no evidence of BCR–ABL fusion transcript detected.